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ABSTRACT
We investigated the concordance of programmed death-ligand 1 (PD-L1) 
expression between primary cancer at initial diagnosis and metastasis at recurrence 
in resected non-small cell lung cancer (NSCLC). PD-L1 expression was evaluated 
using the SP142 assay in 37 NSCLC patients with paired primary lung cancer and 
surgically resected metastases at recurrence. PD-L1 positivity was defined as 
immunohistochemistry (IHC) and also evaluated by RNA in situ hybridization (RISH). 
The concordance rate of PD-L1 between primaries and metastases and correlation with 
clinicopathological factors were analyzed. PD-L1 expression was higher in squamous 
cell carcinoma, wild-type EGFR, and smokers than in non-squamous carcinoma, mutant 
EGFR, and never smokers, respectively. PD-L1 positivity was observed in 18.9% of 
primaries and 21.6% of metastases. IHC demonstrated 78.4% concordance of PD-L1 
positivity between primary and metastatic cancers. In 10.8% of cases, PD-L1 positivity 
was higher in primaries than in metastases, and vice versa in the remaining 10.8%. 
By PD-L1 RISH, 35.1% of primaries and 27.0% of metastases demonstrated PD-L1 
positivity. There was 62.2% concordance in PD-L1 by RISH between the primaries and 
metastases. Our results thus highlight the clinical importance of replacing metastases 
with primary archival tissue, particularly when re-biopsy is difficult at recurrence.
INTRODUCTION
Non-small cell lung cancers (NSCLCs) comprise 
nearly 80% of lung cancers and have a dismal prognosis, 
with an overall 5-year survival rate of only 15% [1]. 
The treatment landscape of NSCLC has transformed 
with the approval of programmed death-1 (PD-1) and 
programmed death ligand-1 (PD-L1) blockade agents 
such as nivolumab, pembrolizumab, atezolizumab, and 
pembrolizumab in patients with ≥50% PD-L1 expression 
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as a front line of therapy [2–7]. PD-1 is expressed on the 
surface of activated T cells [8]. Tumor cells and immune 
cells in the tumor microenvironment can express PD-L1 
and PD-L2 [8, 9]. PD-L1 interaction with PD-1 on T cells 
can induce the downregulation of T-cell function and 
enable tumor growth and persistence through immune 
evasion [8]. These immune checkpoint blockades have 
shown remarkable antitumor activity and long-duration 
response across a wide range of cancer types, including 
NSCLC [8].
Currently, PD-L1 expression evaluated by 
immunohistochemistry (IHC) of formalin-fixed paraffin-
embedded (FFPE) tissue samples is used as a companion 
diagnostic test to predict the response to PD-1 blockade 
[2–5, 10]. Treatment outcomes of PD-1 blockades are 
better in patients whose tumors express higher levels 
of PD-L1 than in those expressing low or no PD-L1 
[11]. Knowledge of PD-L1 status can guide treatment 
decisions; therefore, assays reliably and accurately 
measuring tumor PD-L1 expression levels are warranted 
[11]. PD-L1 expression levels in tumor cells might not be 
consistent, because they can be altered by IFN-γ secretion 
or constitutive oncogene activation [12–15]. Moreover, 
chemotherapy or radiotherapy can affect PD-L1 levels 
of tumor cells and immune cells [12]. Thus, PDL-1 
expression levels can differ between primary lung cancer 
at first diagnosis and metastatic cancer at recurrence [9, 
16, 17]. However, data on the correspondence between 
PDL-1 expression levels at primary lung cancer and 
metastatic sites are limited. Determining whether PDL-1 
expression in archival primary lung cancer is maintained 
in a metastatic site is very important in clinical decision-
making in terms of PD-1 pathway inhibitor therapy. To 
date, no studies have evaluated and compared PD-L1 
expression between primary lung cancer and metastatic 
tumor sites.
PD-L1 positivity has been found to be a 
predictive factor for non-squamous histology but not 
for squamous cell histology [2, 3]. Although PD-L1 
expression is currently a predictive biomarker for PD-1 
blockade, the prediction accuracy is not high enough 
to confirm the drug efficacy. The use of PD-L1 IHC 
to predict response is affected by constraints such as 
intratumoral PD-L1 heterogeneity, PD-L1 expression, 
IHC platforms, detection antibodies, and positivity 
cut-off level [9, 18]. Examining PD-L1 status using 
RNA in situ hybridization (RISH) might circumvent 
these limitations [10, 19, 20]. Velcheti et al. recently 
demonstrated that PD-L1 mRNA expression above the 
detection threshold showed statistically better outcomes 
by RISH than by IHC in two cohorts of NSCLC patients 
[10]. The visualization of RISH facilitates accurate 
determination of the cellular location of tumor cells or 
infiltrating immune cells [10, 19]. Such a technique is 
more accurate than qPCR and is amenable to machine 
learning image analysis.
Here, we aimed to investigate the concordance of 
PD-L1 level between archival primary tumors at initial 
diagnosis and metastasis at recurrence in surgically 
resected NSCLC by IHC and RISH.
RESULTS
Clinicopathological data
The baseline demographics of the 37 patients 
analyzed are summarized in Table 1. The median age of 
patients at diagnosis was 63 years (range, 33–77 years); 
most of the patients were men (73.0%) and current or 
ex-smokers (70.3%). Most cases (27/37, 73.0%) showed 
adenocarcinoma histology. The proportions of stages at the 
initial diagnosis were 56.7% stage I, 24.3% stage II, and 
18.9% stage III. Among 27 adenocarcinoma patients, eight 
harbored EGFR mutations, including L858R at Exon21 
(n = 3), Exon19 deletion (n = 4), and Exon 20 insertion 
(n = 1). The remaining 29 patients (78.3%) harbored wild-
type EGFR. The sites of resected metastatic tumor were 
the lung (20/37, 54.1%), brain (4/37, 10.8%), pleura (5/37, 
13.5%), and others (8/37, 21.6%). The median time from 
initial diagnosis to recurrence was 17.8 months (range, 
2.5–52.5).
PD-L1 expression by IHC in primaries and 
metastases
The IHC method with 5% cut-off points showed 
18.9% (7/32) of primaries and 21.6% (8/37) of metastases 
to be PD-L1 positive. PD-L1 expression was found 
to be correlated with clinicopathological features. In 
primary tumors, higher PD-L1 positivity was observed 
in squamous cell carcinoma (SCC) and wild-type EGFR 
than in adenocarcinoma and mutant EGFR, respectively 
(adenocarcinoma, 13.5% vs. 5.4%, P = 0.005; mutant 
EGFR, 18.9% vs. 0% P = 0.05; Table 2). These findings 
were consistent in both primaries and metastases. Current 
or ex-smoker status tended to increase PD-L1 positivity 
in primary sites (Table 2). Besides these findings, there 
was no significant difference in PD-L1 expression across 
clinical factors (stage, age, sex, and site of metastasis) 
between primaries and metastases. Furthermore, patients 
with EGFR mutations had 0% and 2.7% PD-L1 positivity 
in primaries and metastases, respectively (Table 2).
There was 78.4% concordance of PD-L1 IHC 
staining between primary and metastatic sites (Cohen’s κ 
coefficient = 0.374, 95% CI 0.055–0.693, P = 0.02); in 
10.8% cases, the PD-L1 score of primaries was higher 
than that of metastases, and in the remaining 10.8%, it 
was the other way around (Figure 1, Supplementary 
Figure 1). Thus, PD-L1 status in primary NSCLC can 
predict the PD-L1 status of metastases in almost 80% 
of cases. Semi-quantitative analyses demonstrated that 
the H-score of PD-L1 in primaries corresponded with 
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that in metastases (P = 0.33, Supplementary Figure 2). 
These semi-quantitative data demonstrated that PD-L1 
expression in most cases is consistent between primaries 
and metastases.
PD-L1 by RISH in primary and metastatic sites
According to PD-L1 RISH, 35.1% (13/37) of 
primaries and 27.0% (10/37) of metastases were PD-L1 
positive. PD-L1 RISH positivity tended to be high in 
SCC but low in never/light smokers or individuals with 
EGFR mutation. There was 62.2% concordance in PD-
L1 RISH between primaries and metastases (Cohen’s κ 
coefficient = 0.186, 95% CI −0.139–0.325, P = 0.249); in 
24.3% of cases, the PD-L1 score of primaries was higher 
than that of metastases, and vice versa in 13.5% cases 
(Figure 2, Supplementary Figure 1). We also evaluated the 
concordance across the two different platforms, including 
Table 1: Baseline characteristics
Characteristics Total (n=37)n (%)
Age, year
 Median (Range) 63 (33-77)
Sex
 Male 27 (73.0)
 Female 10 (27.0)
Metastatic sites
 Lung 20 (54.1)
 Pleural 5 (13.5)
 Brain 4 (10.8)
 Others 8 (21.6)
Pathology
 Squamous cell carcinoma 10 (27.0)
 Adenocarcinoma 27 (73.0)
Smoking History
 Never smoker 11 (29.7)
 Ex and current smoker 26 (70.3)
AJCC7 stage
 Stage I 21 (56.7)
 Stage II 9 (24.3)
 Stage III 7 (18.9)
EGFR mutation status
 Exon 19 del 4 (10.8)
 Exon21 L858R 3 (8.1)
 Exon20 insertion 1 (2.7)
Adjuvant chemotherapy
 Yes 21 (56.8)
Surgical biopsy method
 Wedge resection of lung 16 (43.2)
 Lobectomy of lung 3 (8.1)
 Excision 14 (37.8)
 Craniotomy 4 (10.8)
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IHC by SP142 and RISH. Between the two different 
platforms, 66.7% of primaries and 73.0% of metastases 
showed agreement.
Survival outcomes in relation with PD-L1 in 
primaries and metastases
We evaluated the correlation of PD-L1 expression 
by IHC and RISH with the survival outcomes in 37 
patients. Patients without PD-L1 IHC of metastatic lesion 
tended to demonstrate improvement of RFS (18.8 vs. 12.5 
months, P = 0.06) and those without PD-L1 RISH of 
metastasis showed numerical improvement of RFS (18.6 
vs. 15.2 months, P = 0.10; Figure 3). PD-L1 IHC or RISH 
of primary tumor samples was not significantly associated 
with RFS and OS.
DISCUSSION
High PD-L1 expression is used as a biomarker to 
predict the benefit from treatment with PD-1 signaling 
pathway inhibitors in NSCLC [16, 18]. Testing PD-
L1 expression in tumor tissues is mandatory to identify 
patients most likely to respond to anti-PD-1 blockades 
[11]. Therefore, the use of archival primary tumor 
tissue to assess PD-L1 status might help guide decisions 
regarding PD-1 blockade treatment when patients 
experience recurrence after surgery. We conducted this 
study to determine whether PD-L1 expression in primary 
lung cancer is concordant with that in metastatic lung 
cancer when recurrence occurs in NSCLC patients who 
have undergone curative resection. Importantly, almost 
80% of cases demonstrated consistent PD-L1 levels 
between primaries and metastases by PD-L1 IHC. This 
relatively high rate of concordance between primaries 
and metastases provides evidence that primary archival 
tissue can be replaced with metastases, particularly in 
the metastatic setting of resource constraints. In clinical 
practice, we occasionally face difficulties in performing 
biopsies of metastatic sites because of tumor location or 
size, patient comorbidity, etc. However, we should keep in 
mind that because the status of ~20% of cases could still 
change when patients experience recurrence, the re-biopsy 
of a metastasis should be considered for making a precise 
decision. Our findings corroborate recently presented 
data, which showed the rate of concordance for PD-L1 
staining between primaries and metastases to be 77% [21]. 
Since chemotherapy is an important factor changing the 
expression level of PD-L1, we analyzed the correlation 
of chemotherapy and change of PD-L1 in primary and 
metastasis. There is no correlation between previous 
chemotherapy and PD-L1 in our study.
Here, we used the SP142 antibody and considered 
tumors to be positive if at least 5% of cells showed 
membranous staining of any intensity. A concordance of 
nearly 80% between primary and metastatic tumor by 
IHC is reasonable, especially considering that various 
assays only have about 75% concordance, depending on 
how it is measured and what cut-off points and antibodies 
are used [16–18]. Consistent with a previous report, PD-
L1 levels were higher in tumors with SCC histology 
than in adenocarcinomas and lower in mutant EGFR 
than in wild-type EGFR carriers. PD-L1 expression 
in biopsy specimens was recently found to be poorly 
Table 2: Association of PD-L1 of primary and metastasis with clinical factor
Primary PD-L1 
IHC P-value
Metastatic PD-L1 
IHC P-value
Primary PD-L1 
ISH P-value
Metastatic PD-L1 
ISH P-value
positive negative positive negative positive negative positive negative
Histology 0.005 0.012 0.691 0.463
 Adenocarcinoma 2 (5.4%) 26 (70.3%) 3 (8.1%)
25 
(67.6%)
9 
(24.3%)
19 
(51.4%)
7 
(18.9%)
21 
(56.8%)
  Squamous 
carcinoma
5 
(13.5%)
4 
(10.8%)
5 
(13.5%)
4 
(10.8%)
4 
(10.8%)
5 
(13.5%) 3 (8.1%)
6 
(16.2%)
EGFR mutation 0.056 0.038 0.711 0.832
 Mutant 0 (0%) 11 (29.7%) 0 (0%)
11 
(29.7%) 3 (8.1%)
8 
(21.6%) 3 (8.1%)
8 
(21.6%)
 Wild type 7 (18.9%)
19 
(51.4%)
8 
(21.6%)
18 
(48.6%)
10 
(27.0%)
16 
(43.2%)
7 
(18.9%)
19 
(51.4%)
Smoking history 0.064 0.672 0.602 0.639
  Current/ex smoker
7 
(18.9%)
19 
(51.4%)
5 
(13.5%)
21 
(56.8%)
9 
(24.3%)
17 
(45.9%)
7 
(18.9%)
19 
(51.4%)
 Never smoker 0 (0%) 11 (29.7%) 3 (8.1%)
8 
(21.6%)
4 
(10.8%)
7 
(18.9%) 3 (8.1%)
8 
(21.6%)
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correlated with that of the corresponding resected tumor 
in NSCLC patients [16]. Thus, in this study, we excluded 
biopsied samples of metastases, including core and 
bronchoscopic biopsies, to overcome the limitation of 
inter- or intratumoral heterogeneity in cases of small 
biopsied specimens. Our cohort of NSCLC patients had 
undergone surgical resection of metastatic tumor and 
had both primary and matched metastatic tumor samples 
available. We consecutively included NSCLC patients 
who underwent surgical resection, and thus, most had 
adenocarcinoma with single or few metastases and EGFR 
mutations. We reasoned that the inclusion of such patients 
would be a more appropriate indication for surgical 
resection of metastases compared to those with multiple 
and aggressive metastatic features. Our results showed that 
about 20% of primaries were PD-L1 positive and almost 
70% had a score of 0, which is less than that reported 
earlier [11]. The aforementioned less aggressive features 
in our cohort might affect the low frequency of PD-L1 
positivity.
Figure 1: Programmed death-ligand 1 (PD-L1) expression levels in paired surgically resected primary and 
metastatic tissues with representative PD-L1 immunohistochemistry images. Most cases showed concordance of PD-L1 
immunohistochemical (IHC) staining between primary and metastatic sites.
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We also explored the RISH method for detecting 
PD-L1 in primaries and metastases, and compared 
two different platforms—IHC and RISH—in the same 
patient cohort. To our knowledge, this is the first study to 
compare PD-L1 RISH between primaries and metastases 
in a cohort of surgically resected metastatic tumors in 
NSCLC patients. On the basis of RISH positivity scores 
of ≥1, about 60% concordance between primaries and 
metastases was observed, slightly lower than the IHC 
results. Approximately 70% concordance across the two 
different platforms was observed between primaries and 
metastases.
Figure 2: PD-L1 mRNA levels in paired surgically resected primary and metastatic tissues with representative PD-L1 
RNA in situ hybridization (RISH) images. Most patients demonstrated concordance of PD-L1 RISH between primary and metastatic 
sites.
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Our study had several limitations such as selection 
bias owing to the retrospective design, as well as small 
sample size. Hence, our findings should be interpreted 
with caution, and further studies with larger sample sizes 
should be performed to confirm these results. Moreover, 
we could not determine the response to PD-1 blockade 
in this trial because no patient received PD-1 blockade 
therapy.
In conclusion, we demonstrated that the PD-
L1 status of primaries is consistent with that of 
metastases at recurrence in NSCLC. However, re-biopsy 
should be considered with caution to make correct 
immunotherapeutic decisions in NSCLC patients because 
of the inconsistency of PD-L1 status in approximately 
20% of patients.
Figure 3: (A) Median recurrence-free survival (RFS) was 18.86 months for PD-L1 IHC-negative and 12.56 months for PD-L1 IHC-
highly positive samples. (B) Median RFS was 18.66 months for PD-L1 RISH-positive and 15.20 months for PD-L1 RISH-negative.
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MATERIALS AND METHODS
Patients
This study was conducted in a cohort of NSCLC 
patients who underwent surgical resection at Severance 
Hospital in Seoul, Korea, between 2005 and 2012. The 
inclusion criteria were (1) surgical resection of primary 
NSCLC with a curative aim at initial diagnosis, (2) 
surgically resected metastatic lesions at recurrence, (3) 
availability of paired primary and metastatic tumor tissue, 
and (4) availability of clinical data on smoking status and 
survival. Paired tumor samples from 37 patients were used 
for examining PD-L1 expression. Tumors were classified 
according to the seventh American Joint Committee on 
Cancer (AJCC) TNM cancer classification system and the 
World Health Organization system. A predesigned data 
collection format was used to review the patients’ medical 
records for evaluating clinicopathological characteristics 
and survival outcomes. The study was approved by the 
Institutional Review Board of Severance Hospital.
IHC
Sections of FFPE tissues were prepared and stained 
with hematoxylin and eosin. IHC was performed on 
4-μm tissue sections using the Ventana Bench Mark XT 
Autostainer (Ventana Medical Systems, Tucson, AZ, USA) 
and the SP142 antibody (dilution 1:100; Ventana). PD-L1 
positivity was defined as a membranous staining intensity 
of ≥5%. IHC scoring was done on a 0–2 scale (0 = <5%, 
1 = 5%–49%, and 2 = ≥50%) [6]. The semi-quantitative 
H score (maximum value of 300 corresponding to 100% 
of tumor PD-L1-positive cells with an overall staining 
intensity score of 3) was determined by multiplying 
the percentage of stained cells by the intensity score 
(0, absent; 1, weak; 2, moderate; and 3, strong). Two 
experienced pathologists (H.S.S and Y.J.C) blinded to 
the patients’ clinical information examined the PD-L1 
expression. For specimens with discrepant results, two 
pathologists re-evaluated the PD-L1 positivity status to 
reach a consensus after consultation.
RISH
RISH was performed on FFPE sections using the 
ViewRNA® eZ-L assay (Affymetrix, Santa Clara, CA, 
USA) on the Leica Bond III Immunohistochemistry and 
ISH Staining System (Leica Biosystems). Each case was 
assayed using probes for PD-L1. The ViewRNA eZ Check 
Human probe (GAPDH, ACTB, and PPIB) was used as the 
positive control to determine RNA integrity. The Bacillus 
subtilis probe DapB was used as the negative control to 
determine assay background. FFPE sections on slides were 
processed automatically from deparaffinization to ISH 
staining and hematoxylin counterstaining. Briefly, 4-μm-
thick FFPE sections were baked for 1 h at 60 °C and placed 
on the Bond III for processing. Next, slides were rinsed 
with water, air-dried for 30 min at room temperature, 
mounted using Dako Ultramount (Dako, Carpinteria, 
CA, USA), and visualized using a standard bright-field 
microscope. Punctate dot-like red hybridization signals in 
the cytoplasm of tumor cells indicated positive staining. 
RISH scoring was done on a scale of 0–3 as follows: 0, 
<1 dot/cell at 400× magnification; 1, 1–5 dots/cell at 400× 
magnification; 2, 6–20 dots/cell at 400× magnification; 
and 3, >20 dots/cell at 400× magnification. At least three 
high-power fields were analyzed before assigning an RISH 
score to each case.
Statistical analysis
Correlations between immune markers and patient 
characteristics were analyzed using the chi-squared test 
with χ2 correction or Fisher’s exact test for categorical 
variables. To compare dichotomized values, we calculated 
the proportion of discordance between both procedures 
together with 95% confidence intervals, as well as Cohen’s 
κ coefficient of agreement. Survival variables were 
estimated using the Kaplan–Meier method. Categorical 
variables were compared via the log-rank test, and 
quantitative variables by a Cox regression model and the 
associated Wald chi-square statistic. Overall survival (OS) 
was defined as the time from the initial diagnosis until 
death or the most recent follow-up. Relapse-free survival 
(RFS) was measured from the time of surgery to initial 
tumor relapse (local or distant recurrence) or death from 
any cause. Patients with no signs of relapse were censored 
at the most recent follow-up or death. The median follow-
up duration for the overall population was 46.3 months. 
A two-sided P-value of <0.05 was considered statistically 
significant. All the statistical analyses were performed 
using SPSS 20.0 for Windows.
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